Press release
Targeted RNA-Sequencing (RNA-Seq) Market Report for Period 2011 till 2023 Illumina, Roche Holdings, BGI, Eurofins, LabCorp, Berry Genomics, Macrogen, GENEWIZ and Others
Targeted RNA-Sequencing (RNA-Seq) Market
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types.
Request for Free Sample Copy of Global Targeted RNA-sequencing (RNA-Seq) Market 2017 https://goo.gl/1Pt4cP
Top Company Profiles and Analysis included in this report:
Thermo Fisher
Illumina
Roche Holdings
BGI
Eurofins
LabCorp
Berry Genomics
Macrogen
GENEWIZ
Other
Global Targeted RNA-sequencing (RNA-Seq) Market: Key Product Type
Type 1
Type 2
Others
Global Targeted RNA-sequencing (RNA-Seq) Market: Key Application
Research Institutes
Hospitals & Clinics
Biotechnology Company
Others
Global Targeted RNA-sequencing (RNA-Seq) Market: Key Region
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Others)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Others)
South America (Brazil, Argentina, Columbia and Others)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Others)
The Global Targeted RNA-sequencing (RNA-Seq) Market analysis report provides detailed value chain for analysis of Global Targeted RNA-sequencing (RNA-Seq) Market. The value chain helps to analyze major upstream in raw materials, major equipment’s, manufacturing process, downstream customer analysis and major distributor analysis.
The report also covers in-depth description, competitive scenario, wide product portfolio of prime players active in this market and business strategies adopted by competitors along with their SWOT analysis. Side by side, it also explicitly provides information about mergers, acquisitions, joint ventures, and all the other important activities happened in current and past few years. The Global Targeted RNA-sequencing (RNA-Seq) Market report explores manufacturer’s competitive scenario and provides market share for all major players of this market based on production capacity, sales, revenue, geographical presence and other major factors.
Enquire before Buying @ https://goo.gl/1Pt4cP
Table of Contents:
1 Market Overview
1.1 Targeted RNA Sequencing Introduction
1.2 Market Analysis by Type
1.2.1 Type 1
1.2.2 Type 2
1.3 Market Analysis by Applications
1.3.1 Research Institutes
1.3.2 Hospitals & Clinics
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA Market States and Outlook (2012-2022)
1.4.1.2 Canada Market States and Outlook (2012-2022)
1.4.1.3 Mexico Market States and Outlook (2012-2022)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2012-2022)
1.4.2.2 France Market States and Outlook (2012-2022)
1.4.2.3 UK Market States and Outlook (2012-2022)
1.4.2.4 Russia Market States and Outlook (2012-2022)
1.4.2.5 Italy Market States and Outlook (2012-2022)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2012-2022)
1.4.3.2 Japan Market States and Outlook (2012-2022)
1.4.3.3 Korea Market States and Outlook (2012-2022)
1.4.3.4 India Market States and Outlook (2012-2022)
1.4.3.5 Southeast Asia Market States and Outlook (2012-2022).......................Continue https://goo.gl/1Pt4cP
Global Targeted RNA-sequencing (RNA-Seq) Market Research Industry Report is prepared with the help of extensive primary and secondary sources, directories, journals, newsletters and with the help of third-party application like Hoovers, Factiva, Bloomberg, Businessweek, etc.
About Us:
Market Reports Company is a global research and consulting company. We provide customized reports. We can study and analyze any market based on wide range of parameters. We can provide market insights for any particular region, country across the globe within shortest possible turn around time.
What we offer:
• Customized Reports: we provide customized report study on any market or industry.
• Region Specific Study: If you need region specific or if you are searching for particular region market study then, we have expert research team for that.
• How we work: We work in all domains and industries, you name it and we provide the market research industry report analysis of it.
• Expertise: Superior Research Team, 24*7 Customer Care Service
Contact Us
Jason Smith,
Sales Manager, Global Business Development,
Website: http://marketreportscompany.com
Email: jasonsmith@marketreportscompany.com
Contact us: +1-888-220-3424
Address: 20 N State Street, Chicago, Illinois, 60602 United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Targeted RNA-Sequencing (RNA-Seq) Market Report for Period 2011 till 2023 Illumina, Roche Holdings, BGI, Eurofins, LabCorp, Berry Genomics, Macrogen, GENEWIZ and Others here
News-ID: 724263 • Views: …
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
